You are here

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

Last updated on November 14, 2019

FOR MORE INFORMATION
Study Location
Huaiyin District Center for Disease Prevention and Control
Huaian, Jiangsu, 223300 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
42 + days
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of a personally signed and dated ICD indicating that the parent(s)/legal
guardian has been informed of all pertinent aspects of the study.

- Aged 6 weeks (42 days) to

- Healthy infants and children as determined by medical history, physical examination,
and judgment of the investigator.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Participation in other studies involving investigational drug(s)/vaccine(s) since
birth (Cohort 1 only) or in the 6 months prior to study entry (Cohorts 2, 3, and 4)
and/or during study participation.

- Other acute or chronic medical or psychiatric condition, including recent laboratory
abnormality, that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.

- Vaccination with licensed or investigational pneumococcal vaccine.

- Previous vaccination with licensed or investigational Hib vaccine.

NCT03574389
Cheladv74
Not yet recruiting
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

NEED INFO?

Questions about a trial? Call or email to reach a Cheladv74 Clinical Trial Contact Center Representative

Cheladv74 Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Based on your search, you may also be interested in

Pneumococcal Infections, COPD
NCT03276754
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
Official Title  ICMJE A Phase 3 Open-label Trial To Assess The Safety, Tolerability, And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Infants And Young Children In China Who Are Naive To Pneumococcal Vaccination
Brief SummaryThe purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE
  • Pneumococcal Infections
  • Pneumococcal Conjugate Vaccine
Intervention  ICMJE
  • Biological: 13vPnC
    suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
  • Biological: Hib
    suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Study Arms  ICMJE
  • Experimental: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
    1. Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.
    2. Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).
    3. Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.
    4. Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age.
    Intervention: Biological: 13vPnC
  • Active Comparator: Haemophilus influenzae type b (Hib)
    1. No participants in cohort 1 will receive Hib vaccine.
    2. Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.
    3. Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age.
    Intervention: Biological: Hib
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 19, 2018)
656
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 24, 2023
Estimated Primary Completion DateAugust 16, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Evidence of a personally signed and dated ICD indicating that the parent(s)/legal guardian has been informed of all pertinent aspects of the study.
  • Aged 6 weeks (42 days) to <6 years at the time of consent.
  • Healthy infants and children as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria:

  • Participation in other studies involving investigational drug(s)/vaccine(s) since birth (Cohort 1 only) or in the 6 months prior to study entry (Cohorts 2, 3, and 4) and/or during study participation.
  • Other acute or chronic medical or psychiatric condition, including recent laboratory abnormality, that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Vaccination with licensed or investigational pneumococcal vaccine.
  • Previous vaccination with licensed or investigational Hib vaccine.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 42 Days to 5 Years   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Cheladv74 CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03574389
Other Study ID Numbers  ICMJE B1851178
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product:No
Studies a U.S. FDA-regulated Device Product:No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Responsible PartyCheladv74
Study Sponsor  ICMJE Cheladv74
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Cheladv74 CT.gov Call CenterCheladv74
PRS AccountCheladv74
Verification DateJuly 2018

ICMJE     Data element required by the
and the

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Cheladv74 Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]com

Call Now